Annals of Behavioral Medicine

, Volume 50, Issue 5, pp 762–774

A Randomized Controlled Trial to Prevent Depression and Ameliorate Insulin Resistance in Adolescent Girls at Risk for Type 2 Diabetes

  • Lauren B. Shomaker
  • Nichole R. Kelly
  • Courtney K. Pickworth
  • Omni L. Cassidy
  • Rachel M. Radin
  • Lisa M. Shank
  • Anna Vannucci
  • Katherine A. Thompson
  • Sara A. Armaiz-Flores
  • Sheila M. Brady
  • Andrew P. Demidowich
  • Ovidiu A. Galescu
  • Amber B. Courville
  • Cara Olsen
  • Kong Y. Chen
  • Eric Stice
  • Marian Tanofsky-Kraff
  • Jack A. Yanovski
Original Article

Abstract

Background

Prospective data suggest depressive symptoms worsen insulin resistance and accelerate type 2 diabetes (T2D) onset.

Purpose

We sought to determine whether reducing depressive symptoms in overweight/obese adolescents at risk for T2D would increase insulin sensitivity and mitigate T2D risk.

Method

We conducted a parallel-group, randomized controlled trial comparing a 6-week cognitive–behavioral (CB) depression prevention group with a 6-week health education (HE) control group in 119 overweight/obese adolescent girls with mild-to-moderate depressive symptoms (Center for Epidemiological Studies—Depression Scale [CES-D] ≥16) and T2D family history. Primary outcomes were baseline to post-intervention changes in CES-D and whole body insulin sensitivity index (WBISI), derived from 2-h oral glucose tolerance tests. Outcome changes were compared between groups using ANCOVA, adjusting for respective baseline outcome, puberty, race, facilitator, T2D family history degree, baseline age, adiposity, and adiposity change. Multiple imputation was used for missing data.

Results

Depressive symptoms decreased (p < 0.001) in CB and HE from baseline to posttreatment, but did not differ between groups (ΔCESD = −12 vs. −11, 95 % CI difference = −4 to +1, p = 0.31). Insulin sensitivity was stable (p > 0.29) in CB and HE (ΔWBISI = 0.1 vs. 0.2, 95 % CI difference = −0.6 to +0.4, p = 0.63). Among all participants, reductions in depressive symptoms were associated with improvements in insulin sensitivity (p = 0.02).

Conclusions

Girls at risk for T2D displayed reduced depressive symptoms following 6 weeks of CB or HE. Decreases in depressive symptoms related to improvements in insulin sensitivity. Longer-term follow-up is needed to determine whether either program causes sustained decreases in depressive symptoms and improvements in insulin sensitivity.

Trial Registration Number

The trial was registered with clinicaltrials.gov (NCT01425905).

Keywords

Adolescence Depression Insulin resistance Type 2 diabetes Randomized controlled trial 

Copyright information

© The Society of Behavioral Medicine 2016

Authors and Affiliations

  • Lauren B. Shomaker
    • 1
    • 2
    • 3
  • Nichole R. Kelly
    • 1
    • 2
    • 3
  • Courtney K. Pickworth
    • 1
  • Omni L. Cassidy
    • 1
    • 2
  • Rachel M. Radin
    • 1
    • 2
  • Lisa M. Shank
    • 1
    • 2
  • Anna Vannucci
    • 1
    • 2
  • Katherine A. Thompson
    • 1
  • Sara A. Armaiz-Flores
    • 1
  • Sheila M. Brady
    • 1
  • Andrew P. Demidowich
    • 1
  • Ovidiu A. Galescu
    • 1
  • Amber B. Courville
    • 4
  • Cara Olsen
    • 5
  • Kong Y. Chen
    • 6
  • Eric Stice
    • 7
  • Marian Tanofsky-Kraff
    • 1
    • 2
  • Jack A. Yanovski
    • 1
  1. 1.Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)National Institutes of Health (NIH), Hatfield Clinical Research CenterBethesdaUSA
  2. 2.Department of Medical and Clinical PsychologyUniformed Services University of the Health Sciences (USUHS)BethesdaUSA
  3. 3.Department of Human Development and Family Studies and Colorado School of Public HealthColorado State UniversityFort CollinsUSA
  4. 4.Nutrition DepartmentMark O. Hatfield Clinical Center, NIHBethesdaUSA
  5. 5.Biostatistics, Department of Preventive MedicineUniformed Services University of the Health SciencesBethesdaUSA
  6. 6.Diabetes, Endocrinology, and Obesity BranchNational Institute of Diabetes, Digestive and Kidney Diseases, NIHBethesdaUSA
  7. 7.Oregon Research InstituteEugeneUSA

Personalised recommendations